Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancerResearch in context

Summary: Background: Access to immune checkpoint inhibitors remains limited due to cost-effectiveness and affordability concerns. This study evaluates the financial impacts of expanding global access to PD1/PD-L1 inhibitors as first-line monotherapy for patients aged 40–74 years with advanced unres...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Kiu Tay-Teo, Dario Trapani, Manju Sengar, Zeba Aziz, Filip Meheus, André Ilbawi, Elisabeth G.E. de Vries, Lorenzo Moja
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-06-01
Serija:	EClinicalMedicine
Teme:	Non-small cell lung cancer Immune checkpoint inhibitor Access to medicines Economics Finances
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2589537025001932
Oznake:	Označite Brez oznak, prvi označite!